Microarray study of gene expression in uterine leiomyoma

• Дата: 2008
• Автори: Litovkin, K.V., Ivanova, O.V., Bauer, A., Hoheisel, J.D., Bubnov, V.V., Zaporozhan, V.N.
• Формат: Стаття
• Мова: English
• Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2008
• Назва видання: Experimental Oncology
• Теми: Original contributions
• Онлайн доступ: http://dspace.nbuv.gov.ua/handle/123456789/139212
• Назва журналу: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Цитувати: Microarray study of gene expression in uterine leiomyoma / K.V. Litovkin, O.V. Ivanova, A. Bauer, J.D. Hoheisel, V.V. Bubnov, V.N. Zaporozhan // Experimental Oncology. — 2008. — Т. 30, № 2. — С. 106–111. — Бібліогр.: 42 назв. — англ.

Uterine leiomyoma is a most common benign neoplasm in women of reproductive age. It arises from the myometrial compartment of the uterus and may transform in some cases to a malignant phenotype. Aim: To identify the genes involved in pathogenesis of uterine leiomyoma. Methods: We have studied differential gene expression in matched tissue samples of leiomyoma and normal myometrium from the very same people utilizing a cDNA microarray screening method. We also compared our results with previously published microarray data to identify the overlapping gene alterations. Results: Based on this comparison we can divide genes deregulated in our study into two groups. The first group comprises genes that to our knowledge have not been previously reported as deregulated in fibroids: CLDN1, FGF7 (KGF), HNRPM, ISOC1, MAGEC1 (CT7), MAPK12, RFC, TIE1, TNFRSF21 (DR6). The second group consists of genes identified also in previous studies: CCND1 (BCL1), CDKN1A (P21), CRABP2, FN1 and SOX4 (EVI16). In our study FN1 was the most up-regulated gene, occupying the place between the myometrium and fibroids ranging from 2.07 to 3.64, depending of the probe molecule used for detection. Conclusions: Newly identified genes may be regarded as potential diagnostic or prognostic markers of uterine leiomyoma and thus may be very useful as new therapeutic candidates.